JPMorgan Chase & Co. Lowers Revvity (NYSE:RVTY) Price Target to $96.00

Revvity (NYSE:RVTY) had its target price dropped by JPMorgan Chase & Co. from $105.00 to $96.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 11.61% from the stock’s current price.

A number of other research firms have also weighed in on RVTY. Evercore upped their price objective on Revvity from $112.00 to $118.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. Weiss Ratings lowered Revvity from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, March 18th. The Goldman Sachs Group started coverage on Revvity in a research note on Tuesday, December 9th. They set a “neutral” rating and a $105.00 target price for the company. TD Cowen restated a “hold” rating on shares of Revvity in a report on Tuesday, February 3rd. Finally, Wells Fargo & Company increased their price target on Revvity from $107.00 to $110.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 3rd. Five equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $112.92.

Revvity Stock Up 1.5%

Shares of NYSE RVTY traded up $1.23 during midday trading on Tuesday, hitting $86.01. The company’s stock had a trading volume of 233,533 shares, compared to its average volume of 1,325,249. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.68 and a quick ratio of 1.40. The firm has a market capitalization of $9.62 billion, a price-to-earnings ratio of 41.42, a price-to-earnings-growth ratio of 1.78 and a beta of 1.10. The business’s fifty day simple moving average is $97.61 and its two-hundred day simple moving average is $96.56. Revvity has a 1 year low of $81.36 and a 1 year high of $118.30.

Revvity (NYSE:RVTY) last announced its earnings results on Monday, February 2nd. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.55 by $0.15. The firm had revenue of $772.06 million for the quarter, compared to the consensus estimate of $759.81 million. Revvity had a net margin of 8.45% and a return on equity of 7.92%. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.42 EPS. Revvity has set its FY 2026 guidance at 5.350-5.450 EPS. On average, equities analysts predict that Revvity will post 4.94 EPS for the current year.

Hedge Funds Weigh In On Revvity

A number of institutional investors and hedge funds have recently modified their holdings of RVTY. Price T Rowe Associates Inc. MD increased its position in shares of Revvity by 5.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,606,637 shares of the company’s stock worth $832,693,000 after purchasing an additional 434,570 shares in the last quarter. EdgePoint Investment Group Inc. boosted its position in shares of Revvity by 26.3% in the 3rd quarter. EdgePoint Investment Group Inc. now owns 8,574,280 shares of the company’s stock valued at $751,536,000 after purchasing an additional 1,784,620 shares during the period. Janus Henderson Group PLC grew its stake in Revvity by 7.0% during the 4th quarter. Janus Henderson Group PLC now owns 8,161,171 shares of the company’s stock worth $789,595,000 after buying an additional 533,912 shares during the last quarter. Morgan Stanley grew its stake in Revvity by 29.6% during the 4th quarter. Morgan Stanley now owns 2,844,464 shares of the company’s stock worth $275,202,000 after buying an additional 650,083 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its position in Revvity by 22.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,612,116 shares of the company’s stock worth $252,727,000 after buying an additional 486,159 shares during the period. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.